AU2011324870B2 - pan-HER antibody composition - Google Patents

pan-HER antibody composition Download PDF

Info

Publication number
AU2011324870B2
AU2011324870B2 AU2011324870A AU2011324870A AU2011324870B2 AU 2011324870 B2 AU2011324870 B2 AU 2011324870B2 AU 2011324870 A AU2011324870 A AU 2011324870A AU 2011324870 A AU2011324870 A AU 2011324870A AU 2011324870 B2 AU2011324870 B2 AU 2011324870B2
Authority
AU
Australia
Prior art keywords
antibody
antibodies
egfr
her2
her3
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2011324870A
Other languages
English (en)
Other versions
AU2011324870A1 (en
Inventor
Ida K. Christensen
Helle Jacobsen
Michael Kragh
Johan Lantto
Mikkel Wandahl Pedersen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Symphogen AS
Original Assignee
Symphogen AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Symphogen AS filed Critical Symphogen AS
Publication of AU2011324870A1 publication Critical patent/AU2011324870A1/en
Application granted granted Critical
Publication of AU2011324870B2 publication Critical patent/AU2011324870B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2011324870A 2010-11-01 2011-10-31 pan-HER antibody composition Ceased AU2011324870B2 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US40878210P 2010-11-01 2010-11-01
DKPA201000988 2010-11-01
US61/408,782 2010-11-01
DKPA201000988 2010-11-01
DKPA201100672 2011-09-05
DKPA201100672 2011-09-05
US201161531407P 2011-09-06 2011-09-06
US61/531,407 2011-09-06
PCT/IB2011/054834 WO2012059857A2 (en) 2010-11-01 2011-10-31 Pan-her antibody composition

Publications (2)

Publication Number Publication Date
AU2011324870A1 AU2011324870A1 (en) 2013-01-31
AU2011324870B2 true AU2011324870B2 (en) 2015-01-29

Family

ID=59014867

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2011324870A Ceased AU2011324870B2 (en) 2010-11-01 2011-10-31 pan-HER antibody composition
AU2011324871A Ceased AU2011324871B2 (en) 2010-11-01 2011-10-31 Anti-HER3 antibodies and compositions

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2011324871A Ceased AU2011324871B2 (en) 2010-11-01 2011-10-31 Anti-HER3 antibodies and compositions

Country Status (13)

Country Link
US (1) US9217039B2 (enExample)
EP (3) EP3156421B1 (enExample)
JP (2) JP6186277B2 (enExample)
KR (2) KR101862832B1 (enExample)
AU (2) AU2011324870B2 (enExample)
CA (2) CA2816520C (enExample)
DK (1) DK2635604T3 (enExample)
ES (2) ES2692379T3 (enExample)
IL (2) IL225953A0 (enExample)
MX (2) MX347981B (enExample)
PL (1) PL2635604T3 (enExample)
TW (1) TW201231066A (enExample)
WO (2) WO2012059858A1 (enExample)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102137874B (zh) * 2008-08-29 2015-02-18 西福根有限公司 抗表皮生长因子受体的重组抗体组合物
EP2337800B1 (en) 2008-09-15 2013-10-02 Yeda Research and Development Co. Ltd. Antibody combinations and use of same for treating cancer
CA2782571C (en) 2009-12-22 2018-01-23 Roche Glycart Ag Anti-her3 antibodies and uses thereof
US9155802B2 (en) 2010-11-01 2015-10-13 Symphogen A/S Pan-HER antibody composition
EP3156421B1 (en) 2010-11-01 2018-06-06 Symphogen A/S Pan-her antibody composition
US20150231238A1 (en) * 2011-03-15 2015-08-20 Merrimack Pharmaceuticals, Inc. Overcoming resistance to erbb pathway inhibitors
EP2710038B1 (en) * 2011-05-16 2018-01-17 Yeda Research and Development Co. Ltd. COMBINATIONS OF ANTI ErbB ANTIBODIES FOR THE TREATMENT OF CANCER
CA2838695C (en) * 2011-07-01 2017-02-14 Amgen Inc. Mammalian cell culture
AU2012340766B2 (en) 2011-11-23 2018-05-10 Medimmune, Llc Binding molecules specific for HER3 and uses thereof
WO2013148315A1 (en) * 2012-03-27 2013-10-03 Genentech, Inc. Diagnosis and treatments relating to her3 inhibitors
MX358728B (es) * 2012-05-02 2018-09-03 Symphogen As Composiciones de anticuerpos pan-receptor del factor de crecimiento epidermico humano (pan-her) humanizados.
US9180185B2 (en) 2013-01-11 2015-11-10 Hoffman-La Roche Inc. Combination therapy of anti-HER3 antibodies
SI3508502T1 (sl) * 2013-09-20 2023-07-31 Bristol-Myers Squibb Company Kombinacija anti-lag-3 protiteles in anti-pd-1 protiteles za zdravljenje tumorjev
US11305012B2 (en) 2013-09-24 2022-04-19 Medimmune, Llc Binding molecules specific for HER3 and uses thereof
US10745490B2 (en) 2014-04-11 2020-08-18 Celldex Therapeutics, Inc. Anti-ErbB antibodies and methods of use thereof
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
US10526416B2 (en) 2014-09-08 2020-01-07 Yeda Research And Development Co. Ltd. Anti-HER3 antibodies and uses of same
JP2017534574A (ja) 2014-09-08 2017-11-24 イェダ リサーチ アンド ディベロップメント カンパニー リミテッドＹｅｄａ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｄｅｖｅｌｏｐｍｅｎｔ Ｃｏ．Ｌｔｄ． チロシンキナーゼ阻害薬（ｔｋｉ）に耐性のがんを処置するための組成物および方法
CN107001471B (zh) 2014-09-16 2022-01-18 西福根有限公司 抗met抗体和组合物
EP3176183A1 (en) 2015-12-02 2017-06-07 Yeda Research and Development Co. Ltd Compositions and methods for treating cancer not resistant to a tyrosine kinase inhibitor (tki)
MA43416A (fr) 2015-12-11 2018-10-17 Regeneron Pharma Méthodes pour ralentir ou empêcher la croissance de tumeurs résistantes au blocage de l'egfr et/ou d'erbb3
BR112018013407A2 (en) 2015-12-30 2018-12-18 Kodiak Sciences Inc. antibodies and conjugates thereof
US20190151346A1 (en) 2016-05-10 2019-05-23 INSERM (Institute National de la Santé et de la Recherche Médicale) Combinations therapies for the treatment of cancer
CA3185303A1 (en) 2017-04-05 2018-10-11 Symphogen A/S Combination therapies targeting pd-a, tim-3, and lag-3
KR20240155979A (ko) 2017-05-30 2024-10-29 브리스톨-마이어스 스큅 컴퍼니 항-lag-3 항체 또는 항-lag-3 항체 및 항-pd-1 또는 항-pd-l1 항체를 포함하는 조성물
KR102713203B1 (ko) 2017-05-30 2024-10-10 브리스톨-마이어스 스큅 컴퍼니 Lag-3 양성 종양의 치료
SG11202008242XA (en) 2018-03-02 2020-09-29 Kodiak Sciences Inc Il-6 antibodies and fusion constructs and conjugates thereof
AU2019336197A1 (en) 2018-09-07 2021-02-18 Pfizer Inc. Anti-avb8 antibodies and compositions and uses thereof
CN114426578B (zh) * 2019-02-14 2025-03-21 美勒斯公司 结合egfr、her2及her3的结合部分的组合
CA3130248A1 (en) * 2019-02-14 2020-08-20 Merus N.V. Combinations of binding moieties that bind egfr, her2 and her3.
US20220259290A1 (en) * 2019-07-24 2022-08-18 Japan Science And Technology Agency Innovative production technique for antibody-enzyme
US11912784B2 (en) 2019-10-10 2024-02-27 Kodiak Sciences Inc. Methods of treating an eye disorder
AU2021364837A1 (en) 2020-10-23 2023-05-25 Bristol-Myers Squibb Company Lag-3 antagonist therapy for lung cancer
JP7623497B2 (ja) 2020-12-31 2025-01-28 サノフイ ＮＫｐ４６およびＣＤ１２３に結合する多機能性ナチュラルキラー（ＮＫ）細胞エンゲージャ
TW202413419A (zh) 2022-05-27 2024-04-01 法商賽諾菲公司 與ｎｋｐ４６和ｂｃｍａ變體結合之具有ｆｃ工程化的自然殺手（ｎｋ）細胞接合物
EP4713360A1 (en) 2023-05-19 2026-03-25 Les Laboratoires Servier Anti-met antibodies, antibody-drug conjugates, compositions and uses thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000078347A1 (en) * 1999-06-18 2000-12-28 The Victor Chang Cardiac Research Institute Limited Cell growth inhibition
WO2007077028A2 (en) * 2005-12-30 2007-07-12 U3 Pharma Ag Antibodies directed to her-3 and uses thereof
WO2010022736A2 (en) * 2008-08-29 2010-03-04 Symphogen A/S Recombinant anti-epidermal growth factor receptor antibody compositions
WO2010108127A1 (en) * 2009-03-20 2010-09-23 Genentech, Inc. Bispecific anti-her antibodies
WO2011107957A1 (en) * 2010-03-04 2011-09-09 Symphogen A/S Anti-her2 antibodies and compositions

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL126303A (en) 1996-03-27 2002-05-23 Genentech Inc ErbB3 ANTIBODIES
US5968511A (en) 1996-03-27 1999-10-19 Genentech, Inc. ErbB3 antibodies
ES2637801T3 (es) 2000-04-11 2017-10-17 Genentech, Inc. Anticuerpos multivalentes y usos de los mismos
EP1283053A1 (en) 2001-08-09 2003-02-12 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Inhibitors of HER3 activity
MXPA05006724A (es) 2003-01-07 2005-09-08 Symphogen As Metodo para producir proteinas policlonales recombinantes.
WO2004087763A1 (ja) * 2003-03-31 2004-10-14 Chugai Seiyaku Kabushiki Kaisha Ｃｄ２２に対する改変抗体およびその利用
TWI333977B (en) 2003-09-18 2010-12-01 Symphogen As Method for linking sequences of interest
AU2005263334C1 (en) 2004-07-20 2011-01-20 Symphogen A/S A procedure for structural characterization of a recombinant polyclonal protein or a polyclonal cell line
KR20110050567A (ko) 2004-07-22 2011-05-13 제넨테크, 인크. Ｈｅｒ２ 항체 조성물
US20060121044A1 (en) 2004-12-07 2006-06-08 Genentech, Inc. Selecting patients for therapy with a her inhibitor
WO2008031531A1 (en) * 2006-09-15 2008-03-20 F. Hoffmann-La Roche Ag Tumor therapy with a combination of anti-her2 antibodies
PL2129396T3 (pl) * 2007-02-16 2014-02-28 Merrimack Pharmaceuticals Inc Przeciwciała przeciw ERBB3 i ich zastosowania
MX338151B (es) 2007-03-01 2016-04-05 Symphogen As Composiciones de anticuerpo recombinante anti-receptor de factor de crecimiento epidermico.
PL2152872T3 (pl) 2007-05-25 2011-03-31 Symphogen As Sposób wytwarzania rekombinowanego białka poliklonalnego
NZ584684A (en) 2007-11-22 2012-10-26 Symphogen As A method for characterization of a recombinant polyclonal protein
KR20110016899A (ko) 2008-04-23 2011-02-18 심포젠 에이/에스 폴리클로날 단백질을 제조하는 방법
KR20110044905A (ko) 2008-08-15 2011-05-02 메리맥 파마슈티컬즈, 인크. 치료제에 대한 세포의 반응을 예측하는 방법 및 시스템
MX2011003480A (es) * 2008-10-06 2011-04-21 Symphogen As Metodo para identificar y seleccionar candidatos de farmaco para productos de farmacos de combinacion.
MX2011010166A (es) 2009-04-07 2011-10-11 Roche Glycart Ag Anticuerpos biespecificos anti-erbb-3/anti-c-met.
CN102369214B (zh) 2009-04-07 2019-04-12 罗氏格黎卡特股份公司 三价、双特异性抗体
AU2010242914B2 (en) 2009-04-29 2014-11-13 Trellis Bioscience, Llc Improved antibodies immunoreactive with heregulin-coupled HER3
SG177560A1 (en) * 2009-07-06 2012-03-29 Hoffmann La Roche Bi-specific digoxigenin binding antibodies
SG178509A1 (en) * 2009-08-21 2012-04-27 Merrimack Pharmaceuticals Inc Antibodies against the ectodomain of erbb3 and uses thereof
CA2775573A1 (en) 2009-10-09 2011-04-14 Merck Sharp & Dohme Corp. Generation, characterization and uses thereof of anti-her 3 antibodies
KR101806323B1 (ko) 2009-11-13 2017-12-07 다이이치 산쿄 유럽 게엠베하 Ｈｅｒ-３ 관련 질병을 치료하거나 예방하기 위한 물질 및 방법
BR112012025730B1 (pt) 2010-04-09 2020-12-08 Aveo Pharmaceuticals, Inc anticorpo isolado que se liga ao erbb3 humano, seus usos, seu processo de produção e vetor de expressão
PL2606070T3 (pl) * 2010-08-20 2017-06-30 Novartis Ag Przeciwciała dla receptora epidermalnego czynnika wzrostu 3 (her3)
EP3156421B1 (en) 2010-11-01 2018-06-06 Symphogen A/S Pan-her antibody composition

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000078347A1 (en) * 1999-06-18 2000-12-28 The Victor Chang Cardiac Research Institute Limited Cell growth inhibition
WO2007077028A2 (en) * 2005-12-30 2007-07-12 U3 Pharma Ag Antibodies directed to her-3 and uses thereof
WO2010022736A2 (en) * 2008-08-29 2010-03-04 Symphogen A/S Recombinant anti-epidermal growth factor receptor antibody compositions
WO2010108127A1 (en) * 2009-03-20 2010-09-23 Genentech, Inc. Bispecific anti-her antibodies
WO2011107957A1 (en) * 2010-03-04 2011-09-09 Symphogen A/S Anti-her2 antibodies and compositions

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
Coyne, C. et al. 2009 J. Drug Targeting. vol. 17, no. 6, pp. 474-489 *
Huhalov, A. et al. 2010 Cancer Research. vol. 70, no. 8, supp. 1, Ab. 3485 *
Kudwada, S. et al. 2004, Int. J. Cancer, vol. 109, pp. 291-301 *
Larbouret, C. et al. 2007, Clin. Cancer Res. vol. 13, pp. 3356-3362 *
Patel, D. et al. 2009 Int. J. Oncol. vol. 34, pp. 25-32 *

Also Published As

Publication number Publication date
IL225954B (en) 2018-05-31
EP2635605B1 (en) 2018-07-25
EP3156421A1 (en) 2017-04-19
WO2012059857A2 (en) 2012-05-10
JP2014503188A (ja) 2014-02-13
KR20140026336A (ko) 2014-03-05
EP3156421B1 (en) 2018-06-06
TW201231066A (en) 2012-08-01
AU2011324870A1 (en) 2013-01-31
MX2013004897A (es) 2013-07-15
KR101862832B1 (ko) 2018-05-30
CA2816519C (en) 2019-01-15
DK2635604T3 (en) 2017-02-27
WO2012059857A3 (en) 2012-07-19
ES2692379T3 (es) 2018-12-03
JP6186277B2 (ja) 2017-08-23
EP2635604B1 (en) 2016-11-30
AU2011324871B2 (en) 2016-05-19
WO2012059858A1 (en) 2012-05-10
PL2635604T3 (pl) 2017-09-29
JP2014503189A (ja) 2014-02-13
MX348637B (es) 2017-06-22
AU2011324871A1 (en) 2013-05-09
ES2616961T3 (es) 2017-06-14
KR101773120B1 (ko) 2017-08-30
CA2816520A1 (en) 2012-05-10
IL225953A0 (en) 2013-07-31
MX2013004899A (es) 2013-07-15
KR20140026337A (ko) 2014-03-05
EP2635605A4 (en) 2014-10-22
US9217039B2 (en) 2015-12-22
EP2635605A1 (en) 2013-09-11
JP6033783B2 (ja) 2016-11-30
CA2816520C (en) 2017-11-21
EP2635604A2 (en) 2013-09-11
MX347981B (es) 2017-05-22
IL225954A0 (en) 2013-07-31
CA2816519A1 (en) 2012-05-10
US20130287684A1 (en) 2013-10-31

Similar Documents

Publication Publication Date Title
US10221246B2 (en) Pan-HER antibody composition
AU2011324870B2 (en) pan-HER antibody composition
US8609095B2 (en) Anti-HER2 antibodies and compositions
JP6039428B2 (ja) 抗ｈｅｒ２抗体および組成物
EP2844675B1 (en) Humanized pan-her antibody compositions
EP2725036A1 (en) Recombinant anti-epidermal growth factor receptor antibody compositions
JP2016182135A (ja) 抗ｈｅｒ２抗体および組成物
BR112013010718A2 (pt) composição de anticorpo pan-her, composição farmacêutica, método para produção e uso da referida composição
BR112013010764A2 (pt) composição de anticorpos anti-her3, molécula de ligação biespecífica, molécula de ácido nucleico, vetor de expressão, linhagem celular policlonal, método para produção da referida composição, composição farmacêutica e uso da referida composição

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired